Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 11
Submit an article Journal homepage
81
Views
1
CrossRef citations to date
0
Altmetric
Theme: General - Reviews

Assessing post-treatment platelet reactivity: a focus on patient selection and setting

Marc Laine Département de Cardiologie, Hôpital Universitaire Nord, Marseille, FranceCorrespondence[email protected]
,
Corinne Frere INSERM UMRS 1076, Aix-Marseile Université, Faculté de Pharmacie, Marseille, France
,
Olivia Ronsin Service d’Endocrinologie, Hôpital Universitaire Nord, Marseille, France
,
Melanie Gaubert Département de Cardiologie, Hôpital Universitaire Nord, Marseille, France
,
Richard Toesca Pôle RUSH, Hôpital Timone, Marseille, France
,
Jacques Bessereau Pôle RUSH, Hôpital Timone, Marseille, France
,
Pierre Michelet Pôle RUSH, Hôpital Timone, Marseille, France
,
Catherine Gramond Service d’Urgence, Hôpital d’Instruction des Armées Robert PICQUE, Bordeaux, France
,
Olfa Helal Département de Cardiologie, Hôpital Universitaire Nord, Marseille, France
,
Franck Paganelli Département de Cardiologie, Hôpital Universitaire Nord, Marseille, France
&
Laurent Bonello Département de Cardiologie, Hôpital Universitaire Nord, Marseille, France
 show all
Pages 1557-1566 | Published online: 10 Jan 2014

References

  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
  • Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352(12), 1179–1189 (2005).
  • Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497), 1607–1621 (2005).
  • Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur. Heart J. 31(20), 2501–2555 (2010).
  • Mehta S, Yusuf S, Peters R et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527–533 (2001).
  • Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102(6), 624–629 (2000).
  • Schömig A, Neumann F-J, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334(17), 1084–1089 (1996).
  • Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N. Engl. J. Med. 339(23), 1665–1671 (1998).
  • Bertrand ME, Legrand V, Boland J et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 98(16), 1597–1603 (1998).
  • Urban P, Macaya C, Rupprecht HJ et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98(20), 2126–2132 (1998).
  • Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine: prevention, recognition and management. Drug Safety 19(2), 89–98 (1998).
  • Hagihara K, Kazui M, Kurihara A et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab. Dispos. 37(11), 2145–2152 (2009).
  • Kazui M, Nishiya Y, Ishizuka T et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 38(1), 92–99 (2010).
  • Savi P, Pereillo JM, Uzabiaga MF et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84(5), 891–896 (2000).
  • Barragan P, Bouvier J-L, Roquebert P-O et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter. Cardiovasc. Interv. 59(3), 295–302 (2003).
  • Campo G, Fileti L, De Cesare N et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J. Am. Coll. Cardiol. 56(18), 1447–1455 (2010).
  • Campo G, Valgimigli M, Gemmati D et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism?: evidence from a clopidogrel-to-ticlopidine crossover study. J. Am. Coll. Cardiol. 50(12), 1132–1137 (2007).
  • Campo G, Miccoli M, Tebaldi M et al. Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22(6), 399–407 (2011).
  • Campo G, Fileti L, Valgimigli M et al. Poor response to clopidogrel: current and future options for its management. J. Thromb. Thrombolysis 30(3), 319–331 (2010).
  • Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy 29(9), 1089–1102 (2009).
  • Jernberg T, Payne CD, Winters KJ et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27(10), 1166–1173 (2006).
  • Storey RF, Angiolillo DJ, Patil SB et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J. Am. Coll. Cardiol. 56(18), 1456–1462 (2010).
  • Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab. Dispos. 38(9), 1514–1521 (2010).
  • Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25), 2577–2585 (2009).
  • Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
  • Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  • Collet J-P, Silvain J, Landivier A et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the reload with clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelet therapy (RELOAD) study. Circulation 118(12), 1225–1233 (2008).
  • Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb. Res. 121(1), 107–115 (2007).
  • Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica 92(5), 694–697 (2007).
  • Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J. Thromb. Haemost. 3(1), 85–92 (2005).
  • Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12), 919–933 (2010).
  • Järemo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J. Int. Med. 252(3), 233–238 (2002).
  • Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 45(9), 1392–1396 (2005).
  • Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89(5), 783–787 (2003).
  • Gurbel PA, Bliden KP, Samara W et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J. Am. Coll. Cardiol. 46(10), 1827–1832 (2005).
  • Geisler T, Langer H, Wydymus M et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart J. 27(20), 2420–2425 (2006).
  • Gurbel PA, Bliden KP, Guyer K et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J. Am. Coll. Cardiol. 46(10), 1820–1826 (2005).
  • Hochholzer W, Trenk D, Bestehorn H-P et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48(9), 1742–1750 (2006).
  • Blindt R, Stellbrink K, De Taeye A et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb. Haemost. 98(6), 1329–1334 (2007).
  • Price MJ, Endemann S, Gollapudi RR et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29(8), 992–1000 (2008).
  • Bonello L, Paganelli F, Arpin-Bornet M et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost. 5(8), 1630–1636 (2007).
  • Cuisset T, Hamilos M, Sarma J et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am. J. Cardiol. 101(12), 1700–1703 (2008).
  • Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53(10), 849–856 (2009).
  • Breet NJ, Van Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8), 754–762 (2010).
  • Campo G, Valgimigli M, Frangione A, Tebaldi M, Ferrari R. Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. J. Thromb. Haemost. 6(10), 1824–1826 (2008).
  • Campo G, Parrinello G, Ferraresi P et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 57(25), 2474–2483 (2011).
  • Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients. J. Am. Coll. Cardiol. 56(4), 317–318 (2010).
  • Sibbing D, Schulz S, Braun S et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J. Thromb. Haemost. 8(2), 250–256 (2010).
  • Bonello L, Mancini J, Pansieri M et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J. Thromb. Haemost. 10(10), 1999–2005 (2012).
  • Cuisset T, Cayla G, Frere C et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5(3), 325–329 (2009).
  • Cuisset T, Gaborit B, Dubois N et al. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.09.214 (2013) (Epub ahead of print).
  • Mangiacapra F, Patti G, Barbato E et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc. Interv. 5(3), 281–289 (2012).
  • Brar SS, Ten Berg J, Marcucci R et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J. Am. Coll. Cardiol. 58(19), 1945–1954 (2011).
  • Bonello-Palot N, Armero S, Paganelli F et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 104(11), 1511–1515 (2009).
  • Silvain J, Cayla G, Hulot J-S et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur. Heart J. 33(10), 1241–1249 (2012).
  • Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54(8), 2430–2435 (2005).
  • Alexopoulos D, Xanthopoulou I, Panagiotou A et al. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis. Am. J. Kidney Dis. 59(3), 469–471 (2012).
  • Elsenberg EHAM, Van Werkum JW, Van de Wal RMA et al. The influence of clinical characteristics, laboratory and inflammatory markers on “high on-treatment platelet reactivity” as measured with different platelet function tests. Thromb. Haemost. 102(4), 719–727 (2009).
  • Bonello L, Berbis J, Laine M et al. Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. Thromb. Haemost. 108(1), 101–106 (2012).
  • Cesari F, Marcucci R, Caporale R et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb. Haemost. 99(5), 930–935 (2008).
  • Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363(20), 1909–1917 (2010).
  • Chen J, Chen S-Y, Lian J-J, Zeng X-Q, Luo T-C. Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo – a systematic review. Clin. Cardiol. 36(4), 184–189 (2013).
  • Lau WC, Waskell LA, Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 107(1), 32–37 (2003).
  • Park Y, Jeong Y-H, Tantry US et al. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. Eur. Heart J. 33(17), 2151–2162 (2012).
  • Farid NA, Payne CD, Small DS et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther. 81(5), 735–741 (2007).
  • Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. Lancet 376(9749), 1312–1319 (2010).
  • Hulot J-S, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7), 2244–2247 (2006).
  • Collet J-P, Hulot J-S, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660), 309–317 (2009).
  • Hochholzer W, Trenk D, Fromm MF et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol. 55(22), 2427–2434 (2010).
  • Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J. Thromb. Haemost. 6(8), 1439–1441 (2008).
  • Brandt JT, Close SL, Iturria SJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5(12), 2429–2436 (2007).
  • Mega JL, Simon T, Collet J-P et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821–1830 (2010).
  • Jang J-S, Cho K-I, Jin H-Y et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am. J. Cardiol. 110(4), 502–508 (2012).
  • Shuldiner AR, O’Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849–857 (2009).
  • Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4), 512–518 (2010).
  • Lau WC, Gurbel PA, Watkins PB et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109(2), 166–171 (2004).
  • Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354–362 (2009).
  • Bouman HJ, Schömig E, Van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17(1), 110–116 (2011).
  • Sibbing D, Koch W, Massberg S et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur. Heart J. 32(13), 1605–1613 (2011).
  • Hulot J-S, Collet J-P, Cayla G et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ. Cardiovasc. Interv. 4(5), 422–428 (2011).
  • Gong IY, Crown N, Suen CM et al. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur. Heart J. 33(22), 2856–2464a (2012).
  • Campo G, Ferraresi P, Marchesini J, Bernardi F, Valgimigli M. Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J. Thromb. Haemost. 9(10), 2106–2108 (2011).
  • Price MJ, Carson AR, Murray SS et al. First pharmacogenomic analysis using whole exome sequencing to identify novel genetic determinants of clopidogrel response variability: results of the genotype information and functional testing (GIFT) exome study. J. Am. Coll. Cardiol. 59(13), E9 (2012).
  • Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19), 2553–2560 (2009).
  • Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153(1), 66.e9–66.e16 (2007).
  • Michelson AD, Frelinger AL 3rd, Braunwald E et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart J. 30(14), 1753–1763 (2009).
  • Bonello L, Pansieri M, Mancini J et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J. Am. Coll. Cardiol. 58(5), 467–473 (2011).
  • Parodi G, Bellandi B, Venditti F et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am. J. Cardiol. 109(2), 214–218 (2012).
  • Authors/Task Force Members, Steg PG, James SK, Atar D et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur. Heart J. 33(20), 2569–2619 (2012).
  • Hamm CW, Bassand J-P, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32(23), 2999–3054 (2011).
  • Roe MT, Armstrong PW, Fox KAA et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N. Engl. J. Med. 367(14), 1297–1309 (2012).
  • James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 342, d3527 (2011).
  • Gurbel PA, Erlinge D, Ohman EM et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS Platelet Function Substudy. JAMA 308(17), 1785–1794 (2012).
  • Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  • Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121(10), 1188–1199 (2010).
  • Alexopoulos D, Galati A, Xanthopoulou I et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention. J. Am. Coll. Cardiol. 60(3), 193–199 (2012).
  • Parodi G, Valenti R, Bellandi B et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients RAPID (Rapid Activity of Platelet Inhibitor Drugs) Primary PCI Study. J. Am. Coll. Cardiol. 61(15), 1601–1606 (2013).
  • Bliden KP, Tantry US, Storey RF et al. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am. Heart J. 162(1), 160–165 (2011).
  • Bonello L, Camoin-Jau L, Armero S et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 103(1), 5–10 (2009).
  • Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51(14), 1404–1411 (2008).
  • Montalescot G, Sideris G, Meuleman C et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48(5), 931–938 (2006).
  • Alexopoulos D, Xanthopoulou I, Plakomyti T-E et al. Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity. Am. Heart J. 165(1), 73–79 (2013).
  • Cuisset T, Frere C, Quilici J et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc. Interv. 1(6), 649–653 (2008).
  • Valgimigli M, Campo G, de Cesare N et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation 119(25), 3215–3222 (2009).
  • Wang X, Zhang D, Zhuang S, Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin. Cardiol. 34(5), 332–338 (2011).
  • Price MJ, Berger PB, Teirstein PS et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS Randomized Trial. JAMA 305(11), 1097–1105 (2011).
  • Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J. Am. Coll. Cardiol. 59(24), 2159–2164 (2012).
  • Collet J-P, Cuisset T, Rangé G et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 367(22), 2100–2109 (2012).
  • Aradi D, Komócsi A, Price MJ et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int. J. Cardiol. doi:10.1016/j.ijcard.2012.05.100 (2013) (Epub ahead of print).
  • Aradi D, Rideg O, Vorobcsuk A et al. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur. J. Clin. Invest. 42(4), 384–392 (2012).
  • Ari H, Ozkan H, Karacinar A, Ari S, Koca V, Bozat T. The effect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int. J. Cardiol. 157(3), 374–380 (2012).
  • Hazarbasanov D, Velchev V, Finkov B et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J. Thromb. Thrombolysis 34(1), 85–90 (2012).
  • Cutlip DE, Baim DS, Ho KKL et al. Stent thrombosis in the modern Era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103(15), 1967–1971 (2001).
  • Machecourt J, Danchin N, Lablanche JM et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J. Am. Coll. Cardiol. 50(6), 501–508 (2007).
  • Kinnaird TD, Stabile E, Mintz GS et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am. J. Cardiol. 92(8), 930–935 (2003).
  • Steg PG, Huber K, Andreotti F et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur. Heart J. 32(15), 1854–1864 (2011).
  • Rao SV, O’Grady K, Pieper KS et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am. J. Cardiol. 96(9), 1200–1206 (2005).
  • Stone GW. ADAPT-DES one year: A large-scale, multicenter, prospective, observational study of the impact of clopidogrel and aspirin hyporesponsiveness on patient outcomes. TCT 2012; October 25, 2012; Miami, FL.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.